In this podcast, we interview a consultant and a leading patient advocate to better understand and explore the challenges of copay accumulator and maximizer programs for specialty drugs. We discuss the difference between the two programs and their impact on the various stakeholders including the overwhelming burden placed on patients. We also discuss the legal issues and potential policy changes that could eliminate these programs or minimize their impact on patients. Ultimately, our goal is to shed light on this important issue and identify strategies for improving access to critical medications for patients who need them.

Carl Schmid, Executive Director, HIV And Hepatitis Policy Institute

Lauren Crawford Shaver, Senior Managing Director, FTI Consulting

HIV And Hepatitis Policy Institute

FTI Consulting

President's Advisory Council on HIV/AIDS

National Association of Insurance Commissioners. 

Department of Health and Human Services (HHS)

What are co pay maximizers?

Like this episode and want to here more? Check out our past episodes here!

Do you have a prescription for better access? Share your ideas with us at [email protected]

Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)